The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Official Title: A Multicenter, Open-Label, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Study ID: NCT05559541
Brief Summary: This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Tianjin Medical University Cancer Insitute & Hospital, Tianjin, Tianjin, China
Name: Jihui Hao, PhD
Affiliation: Tianjin Medical University Cancer Insitute & Hospital
Role: PRINCIPAL_INVESTIGATOR